Triple Negative Breast Cancer (TNBC) Clinical Trials in Grand Rapids, Michigan

4 studies are recruiting for triple negative breast cancer (tnbc) in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    BAMF Health, Grand Rapids, Michigan
    Locations
    14 in total
    Run by
    Aktis Oncology, Inc.

    See if you can join NCT07020117 on ClinicalTrials.gov

  2. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC). ITI-5000 is a self-amplifying RNA (saRNA) vaccine that instructs the immune system to recognize and attack cancer cells expressing…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Midwest, Grand Rapids, Michigan
    Locations
    2 in total
    Run by
    Immunomic Therapeutics, Inc.

    See if you can join NCT07652242 on ClinicalTrials.gov

  3. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan
    Locations
    18 in total
    Run by
    NiKang Therapeutics, Inc.

    See if you can join NCT07029399 on ClinicalTrials.gov

  4. Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

    The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Midwest, Grand Rapids, Michigan
    Locations
    15 in total
    Run by
    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT05985655 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.